Home Nucleus Oncology RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032

RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032

Overview

The RoE Non-Small Cell Lung Cancer Diagnostics Market is expected to reach a 101.31 USD Million by 2032 and is projected to grow at a CAGR of 15.45% from 2025 to 2032.

Revenue, 2024 (USD Million)
48.18
Forecast, 2032 (USD Million)
101.31
CAGR, 2024 - 2032
15.45%
Report Coverage
RoE

RoE Non-Small Cell Lung Cancer Diagnostics Market 2018-2032 USD Million

RoE Non-Small Cell Lung Cancer Diagnostics Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 48.18 USD Million
  • Projected Market Size (2032): 101.31 USD Million
  • CAGR (2025-2032): 15.45%

Key Findings of RoE Non-Small Cell Lung Cancer Diagnostics Market

  • The RoE Non-Small Cell Lung Cancer Diagnostics Market was valued at 48.18 USD Million in 2024.
  • The RoE Non-Small Cell Lung Cancer Diagnostics Market is likely to grow at a CAGR of 15.45% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Lung Adenocarcinoma (LUAD) in Lung Cancer Type Segment accounted for the largest share of the market with a revenue of 27.44 USD Million
  • The fastest growing segment Imaging Test in Test Segment grew Fastest with a CAGR of 18.73% during the forecast period from 2024 to 2032.

RoE Non-Small Cell Lung Cancer Diagnostics Market Scope

RoE Non-Small Cell Lung Cancer Diagnostics Market Segmentation & Scope
Lung Cancer Type
  • Others
  • Large Cell Carcinoma
  • Lung Squamous CellCarcinoma (LUSC)
  • Lung Adenocarcinoma (LUAD)
Product
  • Services and Softwares
  • Reagents and Kits
  • Instruments
Test
  • Thorecentesis
  • Sputum Cytology
  • Others
  • Biopsy
  • Immunohistochemistry
  • Imaging Test
  • Molecular Test
End User
  • Institutes and Research Centers
  • Academics
  • Hospital
  • Clinical Laboratories

RoE Non-Small Cell Lung Cancer Diagnostics Market Data Coverage Insights

Study Period 2024-2032
Base Year 2020
Unit Revenue in USD Million
Market Value in 2024 48.18 USD Million
Market Value in 2032 101.31 USD Million
CAGR (2025-2032) 15.45%
Historic Data 2016-2023
Market Segments Covered Lung Cancer Type,Product,Test,End User

Regional Insights:

  • Leading Market (2024-2032): RoE, leading in terms of revenue 48.18 USD Million in 2024
    • Key Country: RoE, leading in terms of revenue with value of 48.18 USD Million in 2024.

Segments and Scope

  • RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Lung Cancer Type
    • Lung Adenocarcinoma (LUAD) is the largest segment in RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 27.44 USD Million in the year 2024.
    • Lung Adenocarcinoma (LUAD) is the Fastest growing segment in RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 15.77 % in forecast period 2025-2032.
  • RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Product
    • Instruments is the largest segment in RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 22.63 USD Million in the year 2024.
    • Reagents and Kits is the Fastest growing segment in RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 14.96 % in forecast period 2025-2032.
  • RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Test
    • Imaging Test is the largest segment in RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 20.22 USD Million in the year 2024.
    • Imaging Test is the Fastest growing segment in RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 18.73 % in forecast period 2025-2032.
  • RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032, By End User
    • Clinical Laboratories is the largest segment in RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 22.85 USD Million in the year 2024.
    • Clinical Laboratories is the Fastest growing segment in RoE Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 16.20 % in forecast period 2025-2032.

RoE Non-Small Cell Lung Cancer Diagnostics Market Company Share Analysis

 
Company Name Company Share Analysis
QIAGEN
Quest Diagnostics Incorporated
Abbott
General Electric
F. Hoffmann-La Roche Ltd.
RoE Non-Small Cell Lung Cancer Diagnostics Market Company Share Analysis

RoE Non-Small Cell Lung Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Million

RoE Non-Small Cell Lung Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Million

RoE Non-Small Cell Lung Cancer Diagnostics Market Company Profiling

RoE Non-Small Cell Lung Cancer Diagnostics Market Company Profiling

Industry Related Reports

Asia-Pacific Breast Lesion Localization Methods Market
Europe Breast Lesion Localization Methods Market
North America Breast Lesion Localization Methods Market
Middle East & Africa Breast Lesion Localization Methods Market
South America Breast Lesion Localization Methods Market
Australia Breast Lesion Localization Methods Market
Belgium Breast Lesion Localization Methods Market
Brazil Breast Lesion Localization Methods Market
Canada Breast Lesion Localization Methods Market
China Breast Lesion Localization Methods Market
Frequently Asked Questions
The RoE Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Lung Cancer Type,Product,Test,End User.
RoE Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 48.18(Revenue in USD Million) in 2020.
RoE Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 15.45% during the forecast period of 2024 to 2032.
The Lung Adenocarcinoma (LUAD) segment is expected to dominate the RoE Non-Small Cell Lung Cancer Diagnostics Market, holding a largest market share of 27.44 USD Million in 2024

RoE Non-Small Cell Lung Cancer Diagnostics Market Scope

RoE Non-Small Cell Lung Cancer Diagnostics Market Segmentation & Scope
Lung Cancer Type
  • Others
  • Large Cell Carcinoma
  • Lung Squamous CellCarcinoma (LUSC)
  • Lung Adenocarcinoma (LUAD)
Product
  • Services and Softwares
  • Reagents and Kits
  • Instruments
Test
  • Thorecentesis
  • Sputum Cytology
  • Others
  • Biopsy
  • Immunohistochemistry
  • Imaging Test
  • Molecular Test
End User
  • Institutes and Research Centers
  • Academics
  • Hospital
  • Clinical Laboratories
Frequently Asked Questions
The RoE Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Lung Cancer Type,Product,Test,End User.
RoE Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 48.18(Revenue in USD Million) in 2020.
RoE Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 15.45% during the forecast period of 2024 to 2032.
The estimated market value of the RoE Non-Small Cell Lung Cancer Diagnostics Market for final year is USD 101.31 (USD Million).

RoE Non-Small Cell Lung Cancer Diagnostics Market Company Profiling

RoE Non-Small Cell Lung Cancer Diagnostics Market Company Profiling
Frequently Asked Questions
The RoE Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Lung Cancer Type,Product,Test,End User.
RoE Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 48.18(Revenue in USD Million) in 2020.
RoE Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 15.45% during the forecast period of 2024 to 2032.
The estimated market value of the RoE Non-Small Cell Lung Cancer Diagnostics Market for final year is USD 101.31 (USD Million).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.

BROWSE RELATED PAGES